DNB Asset Management AS Has $69.02 Million Stake in BioMarin Pharmaceutical Inc. $BMRN

DNB Asset Management AS raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,274,284 shares of the biotechnology company’s stock after purchasing an additional 154,954 shares during the quarter. DNB Asset Management AS’s holdings in BioMarin Pharmaceutical were worth $69,015,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BMRN. AQR Capital Management LLC raised its holdings in shares of BioMarin Pharmaceutical by 90.7% in the second quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock valued at $306,429,000 after buying an additional 2,654,768 shares during the last quarter. Norges Bank bought a new stake in BioMarin Pharmaceutical during the 2nd quarter worth about $112,352,000. Viking Global Investors LP increased its position in BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. LSV Asset Management raised its stake in shares of BioMarin Pharmaceutical by 2,445.5% in the third quarter. LSV Asset Management now owns 845,500 shares of the biotechnology company’s stock worth $45,792,000 after acquiring an additional 812,284 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in shares of BioMarin Pharmaceutical during the second quarter valued at approximately $35,202,000. Institutional investors own 98.71% of the company’s stock.

Insider Activity

In other news, EVP Gregory R. Friberg sold 6,326 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total value of $381,963.88. Following the completion of the sale, the executive vice president directly owned 37,578 shares of the company’s stock, valued at $2,268,959.64. This represents a 14.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Wells Fargo called BMRN an attractive buy ahead of the Transcon‑CNP PDUFA, signaling investor interest around the upcoming regulatory decision. Wells Fargo Buy Note
• Positive Sentiment: Sanford C. Bernstein raised its price target from $90 to $94 and kept an outperform rating — a direct positive signal from a major sell‑side shop. Bernstein PT Raise (Benzinga)
• Positive Sentiment: Analysis pieces argue that recent share rebound and DCF assumptions may still imply upside for BMRN, supporting a constructive view for longer‑term investors. Pricing / DCF Upside Analysis
• Neutral Sentiment: Analysts broadly revised forecasts after Q4 results; the coverage is mixed and driving headline activity but not a uniform consensus. Analyst Revisions (Benzinga)
• Neutral Sentiment: BioMarin’s Q4 earnings call highlights were released; investors will parse guidance and R&D updates for implications on cash runway and upcoming catalysts. Q4 Earnings Call Highlights
• Neutral Sentiment: Short‑interest reports flagged a “large increase,” but the filings in the feed show inconsistent/zero values (NaN/0), making the short‑interest signal unreliable for now; not a clear driver.
• Negative Sentiment: HC Wainwright cut its price target to $55 and moved to a neutral rating, a downgrade that reduces near‑term sentiment given the lower target relative to recent levels. HC Wainwright PT Cut (Benzinga)
• Neutral Sentiment: Guggenheim trimmed its target from $106 to $86 but kept a buy rating; Oppenheimer also lowered its target to $95 — mixed signals that compress consensus and increase short‑term volatility. Guggenheim / Oppenheimer Coverage (Benzinga / AmericanBankingNews) Read More.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Oppenheimer dropped their price objective on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research report on Tuesday. Leerink Partners downgraded BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $82.00 to $60.00 in a research report on Wednesday, December 3rd. Piper Sandler decreased their price target on BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Finally, Tudor Pickering set a $88.00 price objective on BioMarin Pharmaceutical in a report on Monday, November 3rd. Fifteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $87.71.

BioMarin Pharmaceutical Stock Down 0.5%

Shares of BioMarin Pharmaceutical stock opened at $61.11 on Friday. The business has a fifty day simple moving average of $58.90 and a 200 day simple moving average of $56.15. The stock has a market cap of $11.74 billion, a PE ratio of 34.33, a price-to-earnings-growth ratio of 0.52 and a beta of 0.26. The company has a quick ratio of 3.10, a current ratio of 5.21 and a debt-to-equity ratio of 0.10. BioMarin Pharmaceutical Inc. has a 12 month low of $50.76 and a 12 month high of $73.51.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.